Page 16 - OHKF_Biotech_EN

1
• Compared to Beijing and Shanghai, Shenzhen has weaker basic
Introduction Figure 3 Biotech companies listed on the STAR research capabilities due to an absence of tertiary institutions

market of the SSE and on the HKEX under
with expertise in biotech. While Shenzhen stands to benefit from

Chapter 18A by location of headquarters
Hong Kong’s advanced research capabilities and world-class
management experience, Hong Kong can also leverage on
20 SSE STAR Market Shenzhen’s industries and enterprises to retain an edge amid keen
HKEX
12 competition. Together, the two cities can develop their biotech
11 industry to a nationally and internationally renowned one.
10
12 Chapter 2 will elaborate in detail the complementary advantages
10 8
of the two cities and the significance of collaborative development.
5
4 The Hetao Shenzhen-Hong Kong Science and Technology
3
3 2 Innovation Cooperation Zone (the Loop) will play a crucial role in
1 0 0 the collaboration of HK-SZ biotech industries. Encompassing the
2016 2017 2018 2019 2020 Shanghai Beijing Suzhou Hong Kong Shenzhen Hong Kong park (i.e., Hong Kong-Shenzhen Innovation and
Technology Park in the Lok Ma Chau Loop) and the Shenzhen
Note: SSE STAR market data as at March 2021. HKEX data as at June 2021, inclusive of park (i.e., the Futian Free Trade Zone and the Huanggang
pre-revenue biotech companies listed after April 2018. Checkpoint area) that straddle the Hong Kong-Shenzhen border,
Sources: Shanghai Stock Exchange, Hong Kong Stock Exchange
the Loop is a national strategic platform centred on I&T
development. As one of the four major collaborative platforms
of the GBA under the 14th Five-Year Plan, the Loop is a priority
8
for the Central authorities and the governments of the two cities.

8 The four major collaborative platforms of the GBA under the 14th Five-Year Plan include the Loop, Qianhai in Shenzhen, Nansha in Guangzhou, and Hengqin in Zhuhai.
14